UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000008223
Receipt number R000009658
Scientific Title The detection of immatire platelet fraction for predicting the recovery from thrombocytopenia after chemotherapy: a prospective observation study.
Date of disclosure of the study information 2012/07/01
Last modified on 2017/06/26 09:12:11

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The detection of immatire platelet fraction for predicting the recovery from thrombocytopenia after chemotherapy: a prospective observation study.

Acronym

The detection of immatire platelet fraction for predicting the recovery from thrombocytopenia after chemotherapy.

Scientific Title

The detection of immatire platelet fraction for predicting the recovery from thrombocytopenia after chemotherapy: a prospective observation study.

Scientific Title:Acronym

The detection of immatire platelet fraction for predicting the recovery from thrombocytopenia after chemotherapy.

Region

Japan


Condition

Condition

Solid tumor

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To develop and validate a model using immature platelet fraction to predict the recovery from thrombocytopenia after chemotherapy.

Basic objectives2

Others

Basic objectives -Others

Observation study

Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

The recovery from thrombocytopenia

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Patients who have solid tumor.
2) Patients who are undergoing chemotherapy with myelosuppressive agents.
3) Patients who are over 18 years of age.
4) Patients who have given written informed consent.

Key exclusion criteria

1) Hemorrhagic and thrombotic disorders
2) Disseminated intravascular coagulation
3) Bone marrow failure
4) Secondary hematopoietic disorders
5) Secondary platelet aggregation
6) Patients considered ineligible for this study

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kenji Tamura

Organization

National Cancer Center Hospital

Division name

Breast and Medical Oncology

Zip code


Address

5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan

TEL

03-3542-2511

Email

ketamura@ncc.go.jp


Public contact

Name of contact person

1st name
Middle name
Last name Emi Noguchi

Organization

National Cancer Center Hospital

Division name

Breast and Medical Oncology

Zip code


Address

5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan

TEL

03-3542-2511

Homepage URL


Email

enoguchi@ncc.go.jp


Sponsor or person

Institute

National Cancer Center Hospital

Institute

Department

Personal name



Funding Source

Organization

National Cancer Center Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

Center for Advanced Medicine and Clinical Research, Nagoya University Graduate School of Medicine

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2012 Year 07 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2012 Year 02 Month 13 Day

Date of IRB


Anticipated trial start date

2012 Year 05 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Immature platelet fraction is measured during chmotherapy.


Management information

Registered date

2012 Year 06 Month 21 Day

Last modified on

2017 Year 06 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009658


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name